Ascendis Pharma A/S
ASNDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAscendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. Valued at $13.52B, ASND is a large-cap name in its sector. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Market Cap
$13.52B
Beta
—
P/E (TTM)
24.81
P/E (Fwd)
19.92
EPS (TTM)
$8.82
EPS (Fwd)
$10.99
ROE
332.6%
ROA
-0.6%
Cash
$572.8M
Total Debt
$896.7M
Free CF
$118.2M
52W Change
25.5%
Annual Financials
Cash vs Debt
Ascendis Pharma A/S carries $896.7M in total debt against $572.8M in cash reserves — debt is roughly 1.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $118.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 332.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $51.2M (2022) to $720.1M (2025), reflecting a 1307% increase over the period.
Investors considering Ascendis Pharma A/S should weigh the typical risks associated with ASND's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ascendis Pharma A/S's trajectory.